<2>Puberty Blockers: Controversial Trial Paused Over Safety Concerns
<3>The Pathways Trial: A Complex Issue
The Pathways trial, a study assessing the effect of puberty blockers on young people with gender incongruence, has been paused due to concerns related to the wellbeing of participants. The UK medicines watchdog, the Medicines and Healthcare Products Regulatory Agency (MHRA), has written to King’s College London, which is leading the trial, to discuss potential amendments that will strengthen the trial protocol.
<4 href='https://who.int/news-room/fact-sheets/detail/gender-identity-disorders' target='_blank'>According to the World Health Organization, gender incongruence is a condition where a person’s gender identity does not align with their sex assigned at birth. The Pathways study was set up after a review of gender services for children and adolescents by the National Health Service (NHS) in the UK.
<5 href='https://nature.com/articles/s41598-022-24613-1' target='_blank'>A study published in Nature suggests that puberty blockers can be an effective treatment for gender dysphoria in adolescents, but the long-term effects of these medications are not